Free Trial

Akebia Therapeutics (AKBA) Competitors

Akebia Therapeutics logo
$3.60 -0.03 (-0.69%)
Closing price 07/3/2025 02:45 PM Eastern
Extended Trading
$3.62 +0.01 (+0.28%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AKBA vs. MRUS, ACLX, ACAD, SWTX, RARE, AAPG, PTGX, RNA, SRRK, and MLTX

Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), Avidity Biosciences (RNA), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Akebia Therapeutics vs. Its Competitors

Akebia Therapeutics (NASDAQ:AKBA) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by insiders. Comparatively, 4.6% of Merus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Merus. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$184.91M5.12-$69.41M-$0.21-17.17
Merus$54.73M68.09-$215.33M-$4.08-13.20

Akebia Therapeutics presently has a consensus price target of $6.75, indicating a potential upside of 87.24%. Merus has a consensus price target of $84.64, indicating a potential upside of 57.20%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Merus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Merus
0 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.14

Akebia Therapeutics has a net margin of -24.51% compared to Merus' net margin of -506.73%. Akebia Therapeutics' return on equity of 0.00% beat Merus' return on equity.

Company Net Margins Return on Equity Return on Assets
Akebia Therapeutics-24.51% N/A -18.92%
Merus -506.73%-35.99%-29.83%

Akebia Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Merus has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

In the previous week, Akebia Therapeutics had 6 more articles in the media than Merus. MarketBeat recorded 8 mentions for Akebia Therapeutics and 2 mentions for Merus. Akebia Therapeutics' average media sentiment score of 0.63 beat Merus' score of 0.56 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akebia Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Merus
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Akebia Therapeutics beats Merus on 10 of the 17 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKBA vs. The Competition

MetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$950.74M$2.43B$5.56B$9.03B
Dividend YieldN/A1.67%5.22%3.99%
P/E Ratio-17.179.3527.6920.25
Price / Sales5.12478.02389.63163.10
Price / CashN/A158.5936.8958.10
Price / Book-15.674.588.035.67
Net Income-$69.41M$31.34M$3.18B$249.21M
7 Day Performance-1.23%3.25%2.93%3.28%
1 Month Performance-9.19%3.46%1.72%3.95%
1 Year Performance285.27%0.77%34.39%20.98%

Akebia Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKBA
Akebia Therapeutics
4.2551 of 5 stars
$3.61
-0.7%
$6.75
+87.2%
+285.3%$950.74M$184.91M-17.17430Insider Trade
MRUS
Merus
1.8428 of 5 stars
$52.60
-0.7%
$84.64
+60.9%
+0.9%$3.64B$54.73M-12.8937
ACLX
Arcellx
2.9622 of 5 stars
$65.85
+0.8%
$111.23
+68.9%
+24.3%$3.63B$107.94M-22.0280
ACAD
ACADIA Pharmaceuticals
4.6238 of 5 stars
$21.57
-2.5%
$27.88
+29.2%
+29.9%$3.61B$996.28M15.74510
SWTX
SpringWorks Therapeutics
1.37 of 5 stars
$46.99
+0.0%
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230Positive News
RARE
Ultragenyx Pharmaceutical
4.0717 of 5 stars
$36.36
-0.4%
$87.00
+139.3%
-4.1%$3.44B$590.69M-6.181,294
AAPG
Ascentage Pharma Group International
N/A$39.38
-0.6%
N/AN/A$3.43B$134.35M0.00600Gap Up
PTGX
Protagonist Therapeutics
2.1142 of 5 stars
$55.27
-0.8%
$66.10
+19.6%
+51.8%$3.43B$434.43M73.69120
RNA
Avidity Biosciences
1.661 of 5 stars
$28.40
-2.2%
$65.59
+130.9%
-25.3%$3.42B$10.90M-9.47190
SRRK
Scholar Rock
3.3413 of 5 stars
$35.42
-1.1%
$42.67
+20.5%
+356.7%$3.36B$33.19M-14.00140
MLTX
MoonLake Immunotherapeutics
1.9912 of 5 stars
$47.20
-0.7%
$74.50
+57.8%
+10.3%$3.02BN/A-20.522News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:AKBA) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners